Suppr超能文献

活检Gleason评分4+3或4+4前列腺癌患者前列腺切除术后病理降期的预测因素。

The predictive factor for pathological downgrading after prostatectomy in patients with biopsy Gleason score 4+3 or 4+4 prostate cancer.

作者信息

Tohi Yoichiro, Matsuda Iori, Fujiwara Kengo, Harada Satoshi, Ito Ayako, Yamasaki Mari, Miyauchi Yasuyuki, Matsuoka Yuki, Kato Takuma, Taoka Rikiya, Tsunemori Hiroyuki, Ueda Nobufumi, Sugimoto Mikio

机构信息

Department of Urology, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.

出版信息

Mol Clin Oncol. 2021 Mar;14(3):56. doi: 10.3892/mco.2021.2218. Epub 2021 Jan 22.

Abstract

The proportion of Gleason pattern (GP) 4 prostate cancers at prostate biopsy has a clinically significant impact on risk stratification for patients with prostate cancer. In pathological diagnosis including GP 4, a biopsy Gleason score (GS) of 3+4 has a more favorable prognosis than a GS of 4+3 and 4+4. However, the discrepancy between biopsy and prostatectomy specimens is well known. The current study investigated the clinical parameters and biopsy specimens associated with pathological downgrading after prostatectomy in biopsies with a GS of 4+3 or 4+4 prostate cancer. A total of 302 patients with prostate cancer who underwent robot-assisted radical prostatectomy between August 2013 and May 2019 were retrospectively reviewed. A total of 103 patients had biopsies with GSs of 4+3 and GS 4+4 (unfavorable pathology). The proportion of patients who were downgraded from unfavorable disease to GS ≤3+4 (favorable pathology) in prostatectomy specimens was investigated. Logistic regression analysis was used to explore the association between clinical parameters and downgrading in prostatectomy specimens. A total of 43 patients (41.7%) were downgraded from biopsy GS to prostatectomy GS. The proportions of downgrade in biopsy GS 4+4 and 4+3 were 14.6 and 27.1%, respectively. The percentage of highest GS out of positive biopsy cores and the maximum percentage of cancer involvement within a positive core with the highest GS were lower in the downgrade group than in the no downgrade group (45 vs. 66.7%, P=0.025; 20 vs. 30%, P=0.048, respectively). When performing multivariate logistic regression analysis, the only significant predictor for downgrade was lower percentage of highest GS cores out of positive biopsy cores (odds ratio, 2.469; 95% confidence interval, 1.029-5.925 P=0.043). In conclusion, patients with biopsy GS 4+4 and 4+3 often exhibit a downgrade to GS 3+4 or less in prostatectomy specimens. The lower percentage of highest GS cores out of positive biopsy cores was associated with downgrade.

摘要

前列腺穿刺活检时Gleason分级模式(GP)4级前列腺癌的比例对前列腺癌患者的风险分层具有临床显著影响。在包括GP 4级的病理诊断中,穿刺活检Gleason评分(GS)为3 + 4的患者预后比GS为4 + 3和4 + 4的患者更有利。然而,穿刺活检与前列腺切除标本之间的差异是众所周知的。本研究调查了GS为4 + 3或4 + 4前列腺癌穿刺活检患者前列腺切除术后与病理降级相关的临床参数和穿刺活检标本。回顾性分析了2013年8月至2019年5月期间共302例行机器人辅助根治性前列腺切除术的前列腺癌患者。共有103例患者的穿刺活检GS为4 + 3和GS 4 + 4(不良病理)。研究了前列腺切除标本中从不良疾病降级为GS≤3 + 4(良好病理)的患者比例。采用逻辑回归分析探讨临床参数与前列腺切除标本降级之间的关联。共有43例患者(41.7%)从穿刺活检GS降级为前列腺切除GS。穿刺活检GS 4 + 4和4 + 3的降级比例分别为14.6%和27.1%。降级组阳性穿刺活检核心中最高GS的百分比以及最高GS阳性核心内癌症累及的最大百分比低于未降级组(分别为45%对66.7%,P = 0.025;20%对30%,P = 0.048)。进行多因素逻辑回归分析时,降级的唯一显著预测因素是阳性穿刺活检核心中最高GS核心的百分比更低(比值比,2.469;95%置信区间,1.029 - 5.925,P = 0.043)。总之,穿刺活检GS为4 + 4和4 + 3的患者在前列腺切除标本中常降级为GS 3 + 4或更低。阳性穿刺活检核心中最高GS核心的百分比更低与降级相关。

相似文献

5
Downgrading of biopsy based Gleason score in prostatectomy specimens.
J Clin Pathol. 2014 Apr;67(4):313-8. doi: 10.1136/jclinpath-2012-201323. Epub 2013 Oct 29.
10
Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):386-91. doi: 10.1016/j.ijrobp.2003.10.014.

本文引用的文献

3
Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2019 Sep 1;17(9):1109-1133. doi: 10.6004/jnccn.2019.0043.
5
Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7?
J Urol. 2018 Mar;199(3):706-712. doi: 10.1016/j.juro.2017.10.014. Epub 2017 Oct 12.
7
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.
8
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
10
Long-term impact of androgen-deprivation therapy on physical function and quality of life.
Cancer. 2015 Jul 15;121(14):2350-7. doi: 10.1002/cncr.29355. Epub 2015 Mar 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验